Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

By Karen Roman Ascentage Pharma Group Internat (Nasdaq: AAPG) said its treatment candidate for B-cell diseases APG-3288 was granted the investigational new drug clearance by the FDA. The company will ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

While multi-indication bispecific therapies are likely to expand in lymphoma, their use must remain driven by efficacy, with ...

The illustration depicts how during differentiation cells normally lose their plasticity and ability to acquire new fates.